ISRCTN71877586 https://doi.org/10.1186/ISRCTN71877586

A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis

Submission date	Recruitment status	[ ] Prospectively registered
19/09/2006	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
27/06/2007	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
15/03/2016	Nutritional, Metabolic, Endocrine	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Neil Wright

Contact details
Sheffield Children's NHS Foundation Trust
Academic Unit of Child Health
C Floor Stephenson Wing
Western Bank
Sheffield
United Kingdom
S10 2TH

Additional identifiers

Protocol serial number
SCH-05-015

Study information

Scientific Title
A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis

Study objectives
To establish a better methodology for identifying patients with Cystic Fibrosis Related Diabetes mellitus (CFRD) and to show that early treatment produces clinical benefits.

Ethics approval required
Old ethics approval format

Ethics approval(s)
West Midlands Research Ethics Committee, 17/10/2005

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Cystic Fibrosis Related Diabetes mellitus (CFRD)

Interventions
Children will be randomised to receive Insulin detemir 0.2 units per kg body weight by once daily subcutanous injection daily for one year. The control group will receive no intervention. There is no placebo or sham treatment (it was not felt appropriate given that it would require a daily injection).

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Insulin detemir

Primary outcome(s)
Measurements of beta-cell function

Key secondary outcome(s)
1. Height, weight, Body Mass Index (BMI), triceps and biceps skin fold thickness
2. Respiratory function testing
3. Three monthly glycosylated haemoglobin
4. Adverse event monitoring

Completion date
01/11/2009

Eligibility

Key inclusion criteria
Any child over ten years of age with either fasting plasma glucose more than 6.1 mmol/l but less than 7.0 mmol/l and/or a two hour glucose of more than 7.8 mmol/l but less than 11.1 mmol/l.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Child

Lower age limit
10 Years

Sex
All

Key exclusion criteria
1. Failure to provide informed consent
2. Pre-existing insulin or oral hypoglycaemic agent treatment

Date of first enrolment
01/10/2006

Date of final enrolment
01/11/2009

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Sheffield Children's NHS Foundation Trust
Sheffield
United Kingdom
S10 2TH

Sponsor information

Organisation
Sheffield Children's NHS Foundation Trust (UK)

ROR
https://ror.org/02md8hv62

Funder(s)

Funder type
Charity

Funder Name
British Society of Paediatric Endocrinology and Diabetes (UK) - Initial funding of £10,000 in November 2004

Funder Name
Sheffield Children's Appeal Charity (UK) - £32,000 in early 2005

Funder Name
Novo Nordisk (UK) - the makers of Detemir; £72,000 (post MREC approval) in summer 2005

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration